{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-020345","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.450506+00:00","generated_at":"2026-06-24T05:34:59.710317+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vericel Q2 revenue $37M, net loss $9M; maintains FY guidance, NexoBrid BLA accepted with PDUFA Jan 2023","bullets":["Total net revenue $37.0M (MACI $28.6M +8% YoY, Epicel $8.2M, NexoBrid $0.2M); net loss $9.0M ($0.19/sh).","Non-GAAP adjusted EBITDA $2.8M (7% margin); operating cash flow $3.1M; cash & investments $131M, no debt.","FY 2022 guidance reaffirmed: total revenue $178-189M, MACI $132-141M, gross margin ~69%, adj. EBITDA margin ~21%.","NexoBrid BLA resubmission accepted by FDA; PDUFA date Jan 1, 2023.","Entered $150M revolving credit facility with J.P. Morgan-led syndicate; issued inaugural ESG report."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-020345","json":"https://secwatch.observer/filing/0001628280-22-020345.json","markdown":"https://secwatch.observer/filing/0001628280-22-020345.md","text":"https://secwatch.observer/filing/0001628280-22-020345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828022020345/0001628280-22-020345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828022020345/vcel-20220803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:34:59.710317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}